Business Context and Reporting Period
This Form 6-K filing by Universe Pharmaceuticals INC covers the month of September 2025. The report details the results of the Company's 2025 Annual General Meeting of Shareholders, which was re-convened on September 2, 2025, following an adjournment on August 26, 2025, due to a lack of quorum. The meeting was held at the Company's principal executive offices in Ji'an, Jiangxi, China.
Key Financial Metrics
The filing text does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance actions and shareholder voting results.
Material Changes and Corporate Actions
The primary material change reported is the shareholder approval of a comprehensive Capital Reorganisation. Key elements include:
- Capital Reduction: Reduction of the par value of issued Ordinary Shares from US$11.25 to US$0.00001, with the credit transferred to a distributable reserve to eliminate accumulated losses.
- Share Sub-division and Alteration: Sub-division of authorized unissued shares and a reduction of authorized share capital from approximately US$134.3 million to US$20,000.
- New Share Classes: Creation of Class A Ordinary Shares (1 vote per share) and Class B Ordinary Shares (100 votes per share, convertible to Class A).
- Share Re-designation: Re-designation of existing holdings into the new Class A and Class B structures.
Guidance, Outlook, and Voting Results
The filing contains no management guidance, financial outlook, or discussion of risks and contingencies beyond the conditions required for the Capital Reorganisation (e.g., Court approval in the Cayman Islands). All eight proposals presented at the meeting were adopted by the shareholders. Notable voting statistics include:
- Quorum: Achieved via adjournment rules with 2.55% of exercisable votes present.
- Director Re-elections: Proposals to re-elect directors Gang Lai, Lin Yang, Jiawen Pang, Ding Zheng, and Yongping Yu passed with "For" votes ranging from 89.62% to 94.23%.
- Capital Reorganisation (Proposal Six): Passed with 75.09% "For" votes.
- Amended Memorandum and Articles (Proposal Seven): Passed with 74.74% "For" votes.
Investor Verification Checklist
- Verify the final approval status of the Capital Reduction by the Grand Court of the Cayman Islands.
- Confirm the effective date of the share sub-division and the issuance of Class A and Class B shares.
- Review the updated capital structure to ensure the elimination of accumulated losses as intended by the distributable reserve transfer.
- Monitor future filings for the first financial report reflecting the new share par value and class structure.